A detailed history of Eagle Bay Advisors LLC transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Eagle Bay Advisors LLC holds 6,717 shares of BMY stock, worth $391,130. This represents 0.2% of its overall portfolio holdings.

Number of Shares
6,717
Previous 7,559 11.14%
Holding current value
$391,130
Previous $313,000 10.86%
% of portfolio
0.2%
Previous 0.19%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 22, 2024

SELL
$39.66 - $51.75 $33,393 - $43,573
-842 Reduced 11.14%
6,717 $347,000
Q2 2024

Jul 26, 2024

SELL
$40.25 - $52.99 $24,592 - $32,376
-611 Reduced 7.48%
7,559 $313,000
Q1 2024

May 08, 2024

BUY
$47.98 - $54.4 $20,391 - $23,120
425 Added 5.49%
8,170 $443,000
Q4 2023

Feb 08, 2024

SELL
$48.48 - $57.85 $15,125 - $18,049
-312 Reduced 3.87%
7,745 $397,000
Q3 2023

Nov 13, 2023

BUY
$57.89 - $64.73 $26,745 - $29,905
462 Added 6.08%
8,057 $467,000
Q2 2023

Aug 10, 2023

SELL
$63.71 - $70.74 $31,345 - $34,804
-492 Reduced 6.08%
7,595 $485,000
Q1 2023

Apr 24, 2023

BUY
$65.71 - $74.53 $1,379 - $1,565
21 Added 0.26%
8,087 $560,000
Q4 2022

Jan 26, 2023

SELL
$68.48 - $81.09 $16,435 - $19,461
-240 Reduced 2.89%
8,066 $0
Q3 2022

Nov 22, 2022

SELL
$0.13 - $76.84 $52 - $30,736
-400 Reduced 4.59%
8,306 $591,000
Q2 2022

Aug 19, 2022

BUY
$72.62 - $79.98 $33,187 - $36,550
457 Added 5.54%
8,706 $670 Million
Q1 2022

May 11, 2022

SELL
$61.48 - $73.72 $11,558 - $13,859
-188 Reduced 2.23%
8,249 $602,000
Q4 2021

Jan 21, 2022

SELL
$53.63 - $62.52 $112,033 - $130,604
-2,089 Reduced 19.85%
8,437 $523,000
Q3 2021

Nov 12, 2021

BUY
$59.17 - $69.31 $167,036 - $195,662
2,823 Added 36.65%
10,526 $623,000
Q2 2021

Jul 30, 2021

BUY
$61.91 - $67.42 $476,892 - $519,336
7,703 New
7,703 $518,000

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $124B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Eagle Bay Advisors LLC Portfolio

Follow Eagle Bay Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Eagle Bay Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Eagle Bay Advisors LLC with notifications on news.